- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02793830
A Mobile Phone Based Medication Reminder Program
27 de janeiro de 2017 atualizado por: Duke University
A Mobile Phone Based Medication Reminder Program for Patients in China With Coronary Heart Disease: A Pilot Study
This study evaluates the feasibility and acceptability of using mobile applications to improve medication adherence.
Participants in the experimental group will receive educational materials and daily reminders through mobile applications.
While, participants in the control group will receive only educational materials.
After the intervention, interviews will be conducted among participants through phone calls.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
The purpose of this study is to improve medication adherence for Chinese patients with coronary heart disease (CHD) by using mobile applications.
An exploratory randomized controlled trial (RCT, N=49) and interviews (n=15) will be included in this pilot study.
The RCT will compare the effects of the medication adherence (MA, n=24) intervention and control condition (n=25) on the MA score (percent of prescribed antihypertensive drugs taken), and health outcomes (SBP and DBP obtained) of patients.
The health outcomes will be assessed at enrollment and every three days after the intervention begins for thirty days.
Feasibility will be determined by the number of patients enrolled, and retention (percent of patients who complete the study).
Acceptability (read daily reminders and educational materials via mobile applications) will be evaluated through focus group interviews.
All analyses will be performed using SAS 9.3 (Cary, NC).
The potential risks of this study are minimal.
Tipo de estudo
Intervencional
Inscrição (Real)
49
Estágio
- Não aplicável
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion criteria for participants are:
- having a medical diagnosis of CHD
- being eighteen years old or older
- having an antihypertensive medication regimen that lasts for forty-nine days or more at the enrollment
- being able to read messages through mobile phone
- having a mobile phone which can receive messages from WeChat, and can receive daily reminders from BB Reminder
- having no obvious cognitive impairment
- patients with comorbidities can be included in the study, but during the study, antihypertensive medications are their only prescribed medications (this will be screened by the cardiologist).
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Mobile App Group
Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
|
Reminders.
Participants will receive medication-taking reminders from the researcher.
These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher).
BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications.
The daily reminders will be sent to participants 15 minutes before every dose of their medications.
Educational materials.
Participants will receive educational materials from the researcher.
These educational materials will be sent through the mobile application-WeChat.
The educational materials include short articles (< 500 words) and/or pictures.
They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health.
The validity of information from it is guaranteed.
The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants.
The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
|
|
Comparador Ativo: Control Group
The control group will receive the same educational materials, but no daily reminder.
|
Educational materials.
Participants will receive educational materials from the researcher.
These educational materials will be sent through the mobile application-WeChat.
The educational materials include short articles (< 500 words) and/or pictures.
They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health.
The validity of information from it is guaranteed.
The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants.
The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in medication adherence score
Prazo: baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
Percent of prescribed antihypertensive drugs taken during the past three days.
|
baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
|
Change in systolic blood pressure (SBP)
Prazo: baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
|
|
Change in diastolic blood pressure (DBP)
Prazo: baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
baseline, day 3, day 6, day 9, day 12, day 15, day 18, day 21, day 24, day 27, day 30.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility as measured by patient enrollment
Prazo: approximately seven weeks
|
Feasibility will be determined by the number of patients enrolled, and retention (percent of patients who complete the study).
|
approximately seven weeks
|
|
Feasibility as measured by patient retention
Prazo: approximately seven weeks
|
Feasibility will be determined by retention (percent of patients who complete the study)
|
approximately seven weeks
|
|
Acceptability as measured by patient interviews
Prazo: approximately seven weeks
|
Acceptability (read daily reminders and educational materials via mobile applications) will be evaluated through interviews.
|
approximately seven weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
11 de julho de 2016
Conclusão Primária (Real)
19 de setembro de 2016
Conclusão do estudo (Real)
12 de novembro de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
3 de junho de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
7 de junho de 2016
Primeira postagem (Estimativa)
8 de junho de 2016
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
30 de janeiro de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
27 de janeiro de 2017
Última verificação
1 de janeiro de 2017
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Pro00073395
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .